Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 109.00K | 151.00K | 165.00K | 163.00K | 205.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.00K | 151.00K | 165.00K | 163.00K | 205.00K |
| Cost of Revenue | 10.48M | 9.71M | 9.64M | 9.49M | 8.01M |
| Gross Profit | -10.37M | -9.56M | -9.48M | -9.33M | -7.80M |
| SG&A Expenses | 4.01M | 3.01M | 3.13M | 3.22M | 3.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.49M | 12.72M | 12.77M | 12.71M | 11.14M |
| Operating Income | -14.38M | -12.57M | -12.60M | -12.55M | -10.93M |
| Income Before Tax | -13.43M | -11.79M | -11.86M | -11.78M | -10.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.43M | -11.79M | -11.86M | -11.78M | -10.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.43M | -11.79M | -11.86M | -11.78M | -10.01M |
| EBIT | -14.38M | -12.57M | -12.60M | -12.55M | -10.93M |
| EBITDA | -14.29M | -12.48M | -12.50M | -12.44M | -10.83M |
| EPS Basic | -0.20 | -0.22 | -0.25 | -0.26 | -0.22 |
| Normalized Basic EPS | -0.13 | -0.14 | -0.16 | -0.16 | -0.14 |
| EPS Diluted | -0.20 | -0.22 | -0.25 | -0.26 | -0.22 |
| Normalized Diluted EPS | -0.13 | -0.14 | -0.16 | -0.16 | -0.14 |
| Average Basic Shares Outstanding | 66.52M | 54.22M | 46.87M | 44.83M | 44.68M |
| Average Diluted Shares Outstanding | 66.52M | 54.22M | 46.87M | 44.83M | 44.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |